



Fig. 1



BEST AVAILABLE COPY

Fig. 2

WT-E1A




BEST AVAILABLE COPY

E1/E3-minus Ad5

Fig. 3


40 pfu/cell 10 pfu/cell not infected



BEST AVAILABLE COPY


E1/E3-minus Ad5

Fig. 4



dl520

BEST AVAILABLE COPY



BEST AVAILABLE COPY

YB-1
↓

MCF-adr


181RDB

257RDB


U2OS

HeLa


Fig. 6



WT-AD5



dl520



dl1119/1131






Fig. 7



BEST AVAILABLE COPY



BEST AVAILABLE COPY

Fig. 10

Control:
No Daunorubicin
Daunorubicin:
40 ng/ml

30
10
C
30
10
C




Fig. 11
Control:
No Daunorubicin
Daunorubicin:
40 ng/ml






Fig. 12




BEST AVAILABLE COPY

Fig. 13

PBS

5×10^8 dl520



BEST AVAILABLE COPY




Fig. 15




Fig. 16 Wildtype Adenovirus





Fig. 17





Fig. 18A



BEST AVAILABLE COPY

Fig. 18B

Not infected 20 pfu Ad312 5 pfu Xvir03




Fig. 19

**Northern Blot Analysis of E2 gene
expression in Ad312 infected cells**




Fig. 20 Northern Blot Analysis of E2 gene expression in infected cells






Fig. 21


XvirPSJL1






HeLa cells infected with
different MOIs of dl520

Fig. 23



BEST AVAILABLE COPY

Fig. 24



BEST AVAILABLE COPY






Fig. 26

U373 cells infected with 10 pfu
dl520/cell after incubation with
 $5\mu M$ Irinotecan for 24 hours




Southern Blot Analysis

Fig. 27
U373 cells infected with 10 pfu dl520/cell
After incubation for 24 hours with
increasing concentrations of Trichostatin




Southern Blot Analysis

Fig. 28
FACS analysis: CAR expression of U373 cells after
incubation with Trichostatin for 24 hours



Oncolytic effect of dl520 in U373 cells in combination
with Irinotecan and Trichostatin

Fig. 29



E1B55k-region:

ORF = 2019 – 3506 bp

BfrI – cleavage site = 3534 bp

3'UTR = 3507 – 4107 bp

E1B55k ORF

E1B55k 3'UTR

1 bp

5300 bp

Bfr I(3534)

Fig. 30

Fig. 31

5'-tgggtactgaaatgtggcttaagggtggaaagaattataag
gtgggggtcttatgttagtttgtatctgttttgcatggccatggc
accaactcggttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
catggccgggtcgtaagaatgtggctccaggcattgtatggcttc
gtcgtcccgcaactctactacccttgcacccatggatcttgcgttgcgtt
ttggagactgcggccgttgcgttgcgttgcgttgcgttgcgttgcgtt
ggatgtgactgtactttgcgttgcgttgcgttgcgttgcgttgcgtt
tcatccgcggcgatgacaagtgtacggctcttggccatggatcttgcgttgcgtt
ccgggaacttaatgtcggttgcgttgcgttgcgttgcgttgcgttgcgtt
ccctgtgaaggctccctcccaatgcgggttaaaacataaaaaccag
actctgttttggattttggatcaaggcaagtgtcttgtctttaggggtttgc

